Amarogentin Inhibits Tumor Stem Cell-Like Features of Lung Cancer by Regulating Notch Signaling

IF 0.4 4区医学 Q4 NUTRITION & DIETETICS

Current Topics in Nutraceutical Research Pub Date : 2023-07-07 DOI:10.37290/ctnr2641-452x.21:215-221

Xiang-qin Wen, Xiaojin Yang

引用次数: 0

Abstract

Amarogentin, a secoiridoid glycoside isolated from the Indian medicinal plant Swertia chirata, is widely known for its antileishmanial, antioxidative, hypoglycemic, antihepatotoxic, antimalarial, anti-inflammatory, and antimicrobial activities. It has been evaluated for its possible anticancerous role in lung cancer using A549 and H1299 cells as models. The results of these studies show a dose-dependent decrease in cell proliferation, cell migration, and invasion by amarogentin. Furthermore, amarogentin repressed stemness in lung cancer, as shown by a diminution in the expression of DLL4, NICD, and Hes1 proteins. In conclusion, we report for the first time the potential regulatory impact of amarogentin on lung cancer. These findings reveal that amarogentin treatment inhibits tumor stem cell-like features in lung cancer by regulating Notch signaling. Therefore, amarogentin may be deemed as a useful therapeutic drug for lung cancer.

查看原文本刊更多论文

紫红素通过调节Notch信号抑制肺癌的肿瘤干细胞样特征

Amarogenin是一种从印度药用植物Swertia chirata中分离出来的醚萜苷，以其抗利什曼原虫、抗氧化、降血糖、抗肝炎、抗疟、抗炎和抗菌活性而广为人知。以A549和H1299细胞为模型，对其在癌症中可能的抗癌作用进行了评估。这些研究的结果表明，苦杏仁素对细胞增殖、细胞迁移和侵袭的影响呈剂量依赖性降低。此外，苦蛋白抑制了癌症中的干性，如DLL4、NICD和Hes1蛋白表达的减少所示。总之，我们首次报道了苦蛋白对癌症的潜在调节作用。这些发现揭示了苦蛋白治疗通过调节Notch信号抑制癌症肿瘤干细胞样特征。因此，苦杏仁素可能被认为是治疗癌症的有效药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Topics in Nutraceutical Research 医学-药学

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Current Topics in Nutraceutical Research is an international, interdisciplinary broad-based peer reviewed scientific journal for critical evaluation of research on chemistry, biology and therapeutic applications of nutraceuticals and functional foods. The major goal of this journal is to provide peer reviewed unbiased scientific data to the decision makers in the nutraceutical and food industry to help make informed choices about development of new products. To this end, the journal will publish two types of review articles. First, a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, a critical evaluation of current human experimental data to help market and deliver the product for medically proven use. This journal will also serve as a forum for nutritionists, internists, neurologists, psychiatrists, and all those interested in preventive medicine. The common denominator of all of the topic to be covered by the journal must include nutraceuticals and/functional food. The following is an example of some specific areas that may be of interest to the journal. i) Role of vitamins, minerals, antioxidants and phytonutrients on cardiovascular health, cancer, diabetes, ocular health, mental health, men’s health, women’s health, infant nutrition, ii) Role of herbals on human health, iii) Dietary supplements and sleep, iv) Components of diet that may have beneficial effect on human health, v) regulation of apoptosis and cell viability, vi) Isolation and characterization of bioactive components from functional foods, vii) Nutritional genomics, and viii) Nutritional proteomics.